FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306255617> ?p ?o ?g. }

• W4306255617 endingPage "75" @default.
• W4306255617 startingPage "75" @default.
• W4306255617 abstract "<strong>Background:</strong> Atherosclerotic cardiovascular diseases (ASCVD) including myocardial infarction, stroke and peripheral arterial disease continue to be major causes of premature death, disability and healthcare expenditure globally. Preventing the accumulation of cholesterol-containing atherogenic lipoproteins in the vessel wall is central to any healthcare strategy to prevent ASCVD. Advances in current concepts about reducing cumulative exposure to apolipoprotein B (apo B) cholesterol-containing lipoproteins and the emergence of novel therapies provide new opportunities to better prevent ASCVD. The present update of the World Heart Federation Cholesterol Roadmap provides a conceptual framework for the development of national policies and health systems approaches, so that potential roadblocks to cholesterol management and thus ASCVD prevention can be overcome. <strong>Methods:</strong> Through a review of published guidelines and research papers since 2017, and consultation with a committee composed of experts in clinical management of dyslipidaemias and health systems research in low-and-middle income countries (LMICs), this Roadmap identifies (1) key principles to effective ASCVD prevention (2) gaps in implementation of these interventions (knowledge-practice gaps); (3) health system roadblocks to treatment of elevated cholesterol in LMICs; and (4) potential strategies for overcoming these. <strong>Results:</strong> Reducing the future burden of ASCVD will require diverse approaches throughout the life-course. These include: a greater focus on primordial prevention; availability of affordable cholesterol testing; availability of universal cholesterol screening for inherited dyslipidaemias; risk stratification moving beyond 10-year risk to look at lifetime risk with adequate risk estimators; wider availability of affordable cholesterol-lowering therapies which should include statins as essential medications globally; use of adequate doses of potent statin regimens; and combination therapies with ezetimibe or other therapies in order to attain and maintain robust reductions in LDL-C in those at highest risk. Continuing efforts are needed on health literacy for both the public and healthcare providers, utilising multi-disciplinary teams in healthcare and applications that quantify both ASCVD risk and benefits of treatment as well as increased adherence to therapies. <strong>Conclusions:</strong> The adverse effects of LDL-cholesterol and apo B containing lipoprotein exposure are cumulative and result in ASCVD. These are preventable by implementation of different strategies, aimed at efficiently tackling atherosclerosis at different stages throughout the human life-course. Preventive strategies should therefore be updated to implement health policy, lifestyle changes and when needed pharmacotherapies earlier with investment in, and a shift in focus towards, early preventive strategies that preserve cardiovascular health rather than treat the consequences of ASCVD." @default.
• W4306255617 created "2022-10-15" @default.
• W4306255617 creator A5001751952 @default.
• W4306255617 creator A5005919719 @default.
• W4306255617 creator A5006206326 @default.
• W4306255617 creator A5010041931 @default.
• W4306255617 creator A5021097809 @default.
• W4306255617 creator A5039271275 @default.
• W4306255617 creator A5041209352 @default.
• W4306255617 creator A5044158736 @default.
• W4306255617 creator A5047938778 @default.
• W4306255617 creator A5048145643 @default.
• W4306255617 creator A5051434092 @default.
• W4306255617 creator A5053901502 @default.
• W4306255617 creator A5055849986 @default.
• W4306255617 creator A5059927593 @default.
• W4306255617 creator A5060657100 @default.
• W4306255617 creator A5060854225 @default.
• W4306255617 creator A5062034086 @default.
• W4306255617 creator A5070499961 @default.
• W4306255617 creator A5073301321 @default.
• W4306255617 creator A5075242638 @default.
• W4306255617 creator A5078515650 @default.
• W4306255617 creator A5086073841 @default.
• W4306255617 creator A5087393973 @default.
• W4306255617 creator A5087751928 @default.
• W4306255617 date "2022-10-14" @default.
• W4306255617 modified "2023-10-16" @default.
• W4306255617 title "World Heart Federation Cholesterol Roadmap 2022" @default.
• W4306255617 cites W112126374 @default.
• W4306255617 cites W121491181 @default.
• W4306255617 cites W1600958960 @default.
• W4306255617 cites W1979948203 @default.
• W4306255617 cites W1997733581 @default.
• W4306255617 cites W2023735564 @default.
• W4306255617 cites W2049308410 @default.
• W4306255617 cites W2052341239 @default.
• W4306255617 cites W2118109560 @default.
• W4306255617 cites W2118184073 @default.
• W4306255617 cites W2119984740 @default.
• W4306255617 cites W2124256749 @default.
• W4306255617 cites W2127427274 @default.
• W4306255617 cites W2142164422 @default.
• W4306255617 cites W2170652936 @default.
• W4306255617 cites W2226817873 @default.
• W4306255617 cites W2289550600 @default.
• W4306255617 cites W2298508936 @default.
• W4306255617 cites W2405171365 @default.
• W4306255617 cites W2466926363 @default.
• W4306255617 cites W2540007944 @default.
• W4306255617 cites W2545952291 @default.
• W4306255617 cites W2552653484 @default.
• W4306255617 cites W2609543937 @default.
• W4306255617 cites W2740003000 @default.
• W4306255617 cites W2765120344 @default.
• W4306255617 cites W2767743404 @default.
• W4306255617 cites W2801534920 @default.
• W4306255617 cites W2806317860 @default.
• W4306255617 cites W2887629426 @default.
• W4306255617 cites W2899669642 @default.
• W4306255617 cites W2900034165 @default.
• W4306255617 cites W2941510061 @default.
• W4306255617 cites W2953804067 @default.
• W4306255617 cites W2963555454 @default.
• W4306255617 cites W2971365948 @default.
• W4306255617 cites W2971515944 @default.
• W4306255617 cites W2980876689 @default.
• W4306255617 cites W2998412955 @default.
• W4306255617 cites W3004830249 @default.
• W4306255617 cites W3007660274 @default.
• W4306255617 cites W3028800184 @default.
• W4306255617 cites W3033499384 @default.
• W4306255617 cites W3037023615 @default.
• W4306255617 cites W3040223903 @default.
• W4306255617 cites W3061843793 @default.
• W4306255617 cites W3092288248 @default.
• W4306255617 cites W3113178943 @default.
• W4306255617 cites W3120916025 @default.
• W4306255617 cites W3129818723 @default.
• W4306255617 cites W3155915093 @default.
• W4306255617 cites W3157291651 @default.
• W4306255617 cites W3174811468 @default.
• W4306255617 cites W3183857127 @default.
• W4306255617 cites W3195904993 @default.
• W4306255617 cites W3196464088 @default.
• W4306255617 cites W3197233987 @default.
• W4306255617 cites W3198898259 @default.
• W4306255617 cites W3205652559 @default.
• W4306255617 cites W3209697344 @default.
• W4306255617 cites W3209760524 @default.
• W4306255617 cites W3210923028 @default.
• W4306255617 cites W3213895219 @default.
• W4306255617 cites W4205177590 @default.
• W4306255617 cites W4206573384 @default.
• W4306255617 cites W4210272691 @default.
• W4306255617 cites W4210443892 @default.
• W4306255617 cites W4214780521 @default.
• W4306255617 cites W4220903911 @default.

• next